Invest in 10,000+ US Stocks and ETFs
* Offering through VF Securities, Inc. (member FINRA/SIPC)
Avadel Pharmaceuticals plc operates as a biopharmaceutical company in the United States. Its lead product candidate is LUMRYZ, a formulation of sodium oxybate, which is in a Phase 3 clinical trial for the treatment of excessive daytime sleepiness or cataplexy in adults with narcolepsy. The company was formerly known as Flamel Technologies SA and changed its name to Avadel Pharmaceuticals plc in January 2017. Avadel Pharmaceuticals plc was incorporated in 2015 and is headquartered in Dublin, Ireland. more
Time Frame | AVDL | Sector | S&P500 |
---|---|---|---|
1-Week Return | 3.9% | -2.27% | -0.57% |
1-Month Return | -13.56% | -3.96% | 1.21% |
3-Month Return | -24.16% | -9.7% | 7.57% |
6-Month Return | -34.61% | -3.37% | 11.45% |
1-Year Return | -27.49% | 3.71% | 28.48% |
3-Year Return | 34.41% | 3.8% | 29.52% |
5-Year Return | 44.31% | 39.78% | 90.66% |
10-Year Return | -35.9% | 106.91% | 203.75% |
Dec '19 | Dec '20 | Dec '21 | Dec '22 | Dec '23 | 5YR TREND | |
---|---|---|---|---|---|---|
Total Revenue | 59.22M | 22.33M | - | 1.50M | 27.96M | [{"date":"2019-12-31","value":100,"profit":true},{"date":"2020-12-31","value":37.72,"profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":2.53,"profit":true},{"date":"2023-12-31","value":47.22,"profit":true}] |
Cost of Revenue | 12.13M | 5.74M | 815.00K | 1.49M | 846.00K | [{"date":"2019-12-31","value":100,"profit":true},{"date":"2020-12-31","value":47.36,"profit":true},{"date":"2021-12-31","value":6.72,"profit":true},{"date":"2022-12-31","value":12.31,"profit":true},{"date":"2023-12-31","value":6.98,"profit":true}] |
Gross Profit | 47.09M | 16.59M | (815.00K) | (1.49M) | 27.12M | [{"date":"2019-12-31","value":100,"profit":true},{"date":"2020-12-31","value":35.23,"profit":true},{"date":"2021-12-31","value":-1.73,"profit":false},{"date":"2022-12-31","value":-3.17,"profit":false},{"date":"2023-12-31","value":57.59,"profit":true}] |
Gross Margin | 79.52% | 74.29% | (Infinity%) | (99.80%) | 96.97% | [{"date":"2019-12-31","value":82,"profit":true},{"date":"2020-12-31","value":76.61,"profit":true},{"date":"2021-12-31","value":null,"profit":false},{"date":"2022-12-31","value":-102.91,"profit":false},{"date":"2023-12-31","value":100,"profit":true}] |
Operating Expenses | 63.92M | 53.25M | 85.60M | 95.22M | 164.97M | [{"date":"2019-12-31","value":38.74,"profit":true},{"date":"2020-12-31","value":32.28,"profit":true},{"date":"2021-12-31","value":51.89,"profit":true},{"date":"2022-12-31","value":57.72,"profit":true},{"date":"2023-12-31","value":100,"profit":true}] |
Operating Income | (16.83M) | (36.66M) | (85.55M) | (98.56M) | (137.85M) | [{"date":"2019-12-31","value":-1682600000,"profit":false},{"date":"2020-12-31","value":-3666100000,"profit":false},{"date":"2021-12-31","value":-8554600000,"profit":false},{"date":"2022-12-31","value":-9856100000,"profit":false},{"date":"2023-12-31","value":-13784900000,"profit":false}] |
Total Non-Operating Income/Expense | (34.24M) | (23.89M) | (17.54M) | (25.22M) | (32.81M) | [{"date":"2019-12-31","value":-3423900000,"profit":false},{"date":"2020-12-31","value":-2389100000,"profit":false},{"date":"2021-12-31","value":-1754100000,"profit":false},{"date":"2022-12-31","value":-2522000000,"profit":false},{"date":"2023-12-31","value":-3281400000,"profit":false}] |
Pre-Tax Income | (38.58M) | (5.08M) | (93.14M) | (111.44M) | (160.78M) | [{"date":"2019-12-31","value":-3858200000,"profit":false},{"date":"2020-12-31","value":-508200000,"profit":false},{"date":"2021-12-31","value":-9314500000,"profit":false},{"date":"2022-12-31","value":-11143900000,"profit":false},{"date":"2023-12-31","value":-16077700000,"profit":false}] |
Income Taxes | (5.36M) | (12.11M) | (15.82M) | 26.02M | (501.00K) | [{"date":"2019-12-31","value":-20.58,"profit":false},{"date":"2020-12-31","value":-46.53,"profit":false},{"date":"2021-12-31","value":-60.77,"profit":false},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":-1.93,"profit":false}] |
Income After Taxes | (33.23M) | 7.03M | (77.33M) | (137.46M) | (160.28M) | [{"date":"2019-12-31","value":-472.77,"profit":false},{"date":"2020-12-31","value":100,"profit":true},{"date":"2021-12-31","value":-1100.3,"profit":false},{"date":"2022-12-31","value":-1955.95,"profit":false},{"date":"2023-12-31","value":-2280.54,"profit":false}] |
Income From Continuous Operations | (33.23M) | 7.03M | (77.33M) | (137.46M) | (160.28M) | [{"date":"2019-12-31","value":-472.77,"profit":false},{"date":"2020-12-31","value":100,"profit":true},{"date":"2021-12-31","value":-1100.3,"profit":false},{"date":"2022-12-31","value":-1955.95,"profit":false},{"date":"2023-12-31","value":-2280.54,"profit":false}] |
Income From Discontinued Operations | - | - | - | - | - | [{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}] |
Net Income | (33.23M) | 7.03M | (77.33M) | (137.46M) | (160.28M) | [{"date":"2019-12-31","value":-472.77,"profit":false},{"date":"2020-12-31","value":100,"profit":true},{"date":"2021-12-31","value":-1100.3,"profit":false},{"date":"2022-12-31","value":-1955.95,"profit":false},{"date":"2023-12-31","value":-2280.54,"profit":false}] |
EPS (Diluted) | (0.89) | (0.56) | (1.32) | (2.25) | (2.01) | [{"date":"2019-12-31","value":-89,"profit":false},{"date":"2020-12-31","value":-56,"profit":false},{"date":"2021-12-31","value":-132,"profit":false},{"date":"2022-12-31","value":-225,"profit":false},{"date":"2023-12-31","value":-201,"profit":false}] |
These ratios help you determine the liquidity of the company. Higher is better.
AVDL | |
---|---|
Cash Ratio | 1.54 |
Current Ratio | 2.97 |
Quick Ratio | 2.60 |
These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.
AVDL | |
---|---|
ROA (LTM) | -34.45% |
ROE (LTM) | -99.52% |
These ratios help you understand the company's liabilities, gauging the riskiness of the investment.
AVDL | |
---|---|
Debt Ratio Lower is generally better. Negative is bad. | 0.53 |
Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. | 0.47 |
These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.
AVDL | |
---|---|
Trailing PE | NM |
Forward PE | 15.50 |
P/S (TTM) | 7.25 |
P/B | 13.41 |
Price/FCF | NM |
EV/R | 6.78 |
EV/Ebitda | NM |
PEG | 0.07 |
Avadel Pharmaceuticals PLC (AVDL) share price today is $10.39
Yes, Indians can buy shares of Avadel Pharmaceuticals PLC (AVDL) on Vested. To buy Avadel Pharmaceuticals PLC from India, you can open a US Brokerage account on Vested today by clicking on Sign Up or Invest in AVDL stock at the top of this page. The account opening process is completely digital and secure, and takes a few minutes to complete.
Yes, you can purchase fractional shares of Avadel Pharmaceuticals PLC (AVDL) via the Vested app. You can start investing in Avadel Pharmaceuticals PLC (AVDL) with a minimum investment of $1.
You can invest in shares of Avadel Pharmaceuticals PLC (AVDL) via Vested in three simple steps:
The 52-week high price of Avadel Pharmaceuticals PLC (AVDL) is $19.09. The 52-week low price of Avadel Pharmaceuticals PLC (AVDL) is $9.41.
The price-to-earnings (P/E) ratio of Avadel Pharmaceuticals PLC (AVDL) is
The price-to-book (P/B) ratio of Avadel Pharmaceuticals PLC (AVDL) is 13.41
The dividend yield of Avadel Pharmaceuticals PLC (AVDL) is 0.00%
The market capitalization of Avadel Pharmaceuticals PLC (AVDL) is $1.27B
The stock symbol (or ticker) of Avadel Pharmaceuticals PLC is AVDL